BA.1和BA.4/BA.5 SARS-CoV-2二价加强针的免疫原性：COVAIL随机临床试验的初步结果
Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial.
作者信息
Branche Angela R, Rouphael Nadine G, Losada Cecilia, Baden Lindsey R, Anderson Evan J, Luetkemeyer Anne F, Diemert David J, Winokur Patricia L, Presti Rachel M, Kottkamp Angelica C, Falsey Ann R, Frey Sharon E, Rupp Richard, Bäcker Martín, Novak Richard M, Walter Emmanuel B, Jackson Lisa A, Little Susan J, Immergluck Lilly C, Mahgoub Siham M, Whitaker Jennifer A, Babu Tara M, Goepfert Paul A, Fusco Dahlene N, Atmar Robert L, Posavad Christine M, Netzl Antonia, Smith Derek J, Telu Kalyani, Mu Jinjian, Makowski Mat, Makhene Mamodikoe K, Sonja Crandon, Montefiori David C, Roberts Paul C, Beigel John H
机构信息
University of Rochester VTEU, Rochester, NY.
Emory University Hope Clinic, Decatur, GA.
出版信息
medRxiv. 2023 Mar 31:2023.01.31.23285306. doi: 10.1101/2023.01.31.23285306.
In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent SARS-CoV-2 mRNA vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wildtype spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers against currently circulating Omicron subvariants for both bivalent vaccines.
在一项随机临床试验中，我们比较了基于BA.1或BA.4/BA.5奥密克戎刺突蛋白与野生型刺突蛋白组合的二价SARS-CoV-2 mRNA疫苗加强接种后的早期中和抗体反应。两种二价疫苗针对SARS-CoV-2变体的反应在针对当前流行的奥密克戎亚变体的滴度上下降幅度最大。
Zotero 插件